Stimulants for cognitive enhancement — particularly in patients without diagnosed ADHD — is a clinical and ethical area where prescribing practice has evolved substantially over the past two decades. The reality is that stimulant prescriptions have increased substantially across the lifespan; some of this reflects appropriate recognition of previously underdiagnosed ADHD, some reflects expansion into subthreshold and enhancement use. The longevity-psychiatry frame engages this thoughtfully — recognizing legitimate ADHD treatment, addressing the underlying issues that may produce ADHD-like symptoms, and being honest about the limits of stimulants as general cognitive enhancement.
The diagnostic discipline matters. ADHD diagnosis requires the DSM-5 criteria — symptoms present before age 12, current symptoms producing impairment across multiple settings, exclusion of alternative explanations. The patient with stress-related concentration difficulty at work, sleep-deprived attentional decrement, untreated depression producing cognitive complaints, or anxiety-driven distraction is not diagnostically ADHD — they have other conditions that respond to other treatment. The diagnostic discipline matters because the treatment and management differ.
The cognitive enhancement literature in healthy adults is more limited than the popular narrative suggests. Meta-analyses of stimulants in healthy adults show small effect sizes on specific cognitive tasks (working memory, vigilance under fatigue, certain attention tasks) and minimal effect on broader cognition. The narrative of stimulants as transformative cognitive enhancers in healthy individuals exceeds the evidence. The patient who is well-rested, well-managed in mood and anxiety, and engaged in cognitively-demanding work is unlikely to experience dramatic cognitive enhancement from stimulants; the marginal benefit is small.
The underlying issues frequently matter more than stimulant prescription. Sleep deprivation produces measurable cognitive impairment that no stimulant fully reverses; addressing sleep produces larger cognitive benefit than any pharmacological intervention. Untreated mood or anxiety disorders produce cognitive complaints that resolve with treatment of the underlying condition. Substance use (alcohol, marijuana, others) produces ongoing cognitive cost. The patient seeking cognitive enhancement frequently has a specific addressable issue that warrants attention before stimulant prescription is considered.
The responsible practice frame. Engage seriously with ADHD evaluation for patients with credible clinical picture and developmental history. Address the underlying contributors that produce ADHD-like symptoms without warranting stimulant treatment. Be honest about the limits of stimulants as general cognitive enhancement. Decline requests for stimulant prescription in patients without diagnosis or clear clinical indication. The clinical relationship is preserved when the conversation is honest; "I don't think stimulants are the right answer here, and here's what I think is" is appropriate care. The discipline is to treat diagnosed ADHD appropriately, address underlying issues thoroughly, and resist the casual extension of stimulant prescription into cognitive enhancement use that the evidence does not support.